由FUS突变引起的肌缩性侧面硬化症:具有广泛影响的进展
Thomas G Moens1, Sandrine Da Cruz2, Manuela Neumann3
1Department of Neurosciences, and Leuven Brain Institute, University of Leuven, Leuven, Belgium; Laboratory of Neurobiology, Center for Brain & Disease Research, VIB, Leuven, Belgium; CRUK Scotland Institute, Glasgow, UK.
The Lancet. Neurology
|January 25, 2025
概括
FUS基因的突变导致一种罕见的肌缩性侧面硬化症 (ALS),称为FUS-ALS,导致早期发病和疾病的快速进展. 针对FUS表达的治疗策略正在开发中.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- FUS基因的自体主导突变与肌缩性侧面硬化症 (ALS) 有关.
- 在0.3-0.9%的ALS患者中发现了FUS突变,导致FUS-ALS,一种早期发病和快速进展的疾病.
- 由于核局部破坏而导致FUS蛋白在细胞质积累是FUS-ALS的标志.
研究的目的:
- 总结FUS突变相关ALS (FUS-ALS) 的遗传基础,临床特征和病原性机制.
- 为了突出FUS-ALS和前性痴呆症之间的差异.
- 审查FUS-ALS目前的治疗策略.
主要方法:
- 在FUS-ALS.中的遗传和神经病理发现的审查.
- 分析实验模型以了解疾病机制.
- 目前正在开发的治疗方法的概述.
主要成果:
- 在ALS中,FUS突变导致不同的临床表现,发病年龄和进展率各不相同.
- 在FUS-ALS和一些前性痴呆病例中都观察到FUS蛋白质含有,但具有关键的遗传和病理差异.
- 实验模型已经阐明了FUS-ALS.的潜在致病途径.
结论:
- FUS突变代表了ALS的独特遗传原因,具有特定的临床和病理特征.
- 了解FUS蛋白在神经退行过程中的作用对于开发向疗法至关重要.
- 静止FUS表达的反意义寡核酸治疗是一种有前途的治疗策略,目前正在为FUS-ALS开发.
相关概念视频
03:03Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
01:15Parkinson's Disease: Overview
451
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
451